Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
By: Anubha Agarwal and Mark D. Huffman
References
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326: 1419. DOI: 10.1136/bmj.326.7404.1419
- World Health Organization. WHO EML 23rd List. 2023.
https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1 . - Zhu JZ, Manne-Goehler J, Agarwal A, et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. J Am Coll Cardiol. 2023; 81: 620–2. DOI: 10.1016/j.jacc.2022.12.003
- Castellano JM. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022; 387: 967–977. DOI: 10.1056/NEJMoa2208275
- Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76: 2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014; 371: 818–27. DOI: 10.1056/NEJMoa1311890
- Kishore SP, Blank E, Heller DJ, et al. Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases. J Am Coll Cardiol. 2018; 71: 564–74. DOI: 10.1016/j.jacc.2017.11.056
DOI: https://doi.org/10.5334/gh.1310 | Journal eISSN: 2211-8179
Language: English
Submitted on: Feb 5, 2024
Accepted on: Feb 12, 2024
Published on: Feb 26, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2024 Anubha Agarwal, Mark D. Huffman, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.